.png){kind=icon}
返回
FDA/M-CERSI Co-Processed API Workshop Proceedings
.png){kind=icon}
PRE
AI
DOI：10.1016/j.xphs.2023.01.006.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
These proceedings contain presentation summaries and discussion highlights from the University of Mary-land Center of Excellence in Regulatory Science and Innovation (M-CERSI) Workshop on Co-processed API, held on July 13 and 14, 2022. This workshop examined recent advances in the use of co-processed active pharmaceutical ingredients as a technology to improve drug substance physicochemical properties and drug product manufacturing process robustness, and explored proposals for enabling commercialization of these transformative technologies. Regulatory considerations were discussed with a focus on the classification, CMC strategies, and CMC documentation supporting the use of this class of materials from clinical studies through commercialization. The workshop format was split between presentations from industry, academia and the FDA, followed by breakout sessions structured to facilitate discussion. Given co-processed API is a relatively new concept, the authors felt it prudent to compile these proceedings to gain further visibility to topics discussed and perspectives raised during the workshop, particularly during breakout discussions. Disclaimer: This paper reflects discussions that occurred among stakeholder groups, including FDA, on vari-ous topics. The topics covered in the paper, including recommendations, therefore, are intended to capture key discussion points. The paper should not be interpreted to reflect alignment on the different topics by the participants, and the recommendations provided should not be used in lieu of FDA published guidance or direct conversations with the Agency about a specific development program. This paper should not be con-strued to represent FDA's views or policies.& COPY; 2023 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.
Keyword:
Co-processing
Co-processed API
Regulatory
Particle engineering
期刊
IF:
3.8
论文数:
1.1W
被引数:
2.6W
机构
引用论文
Rotational behaviour produced by intranigral injections of bovine and human ?-casomorphins in rats
PREAI
分享收藏Manipulating Cocrystal Size and Morphology using a Combination of Temperature Cycling and Additives
OAAI
OAAI分享收藏Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective优化蛋白水解靶向嵌合体 (PROTACs) 用于口服药物递送: 药物代谢和药代动力学观点.png)
DRUG DISCOVERY TODAY
DRUG DISCOVERY TODAYIF7.5
PREAI
分享收藏
How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets超越5种药物和临床候选药物的规则如何与其靶标结合
PREAI
分享收藏
查看更多内容